# Indivior Pharmaceuticals, Inc.: filings

INDV · Nasdaq · CIK 1625297 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/indv.md) · [Financials](/companies/indv/financials.md) · [Filings](/companies/indv/filings.md) · [Insiders](/companies/indv/insiders.md)

## Reports and events: 406 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (6-K 337, 4 39, 8-K 35, SCHEDULE 13D/A 15, 3 13, 144 10, 425 8, SCHEDULE 13G 7, 10-Q 6, SCHEDULE 13G/A 6, SC 13G 5, DFAN14A 4, DRS/A 4, SC 13D/A 4, UPLOAD 4, 20FR12B/A 3, 6-K/A 3, 8-K/A 3, DRSLTR 3, S-8 3, S-8 POS 3, SC 13G/A 3, 10-K 2, 20FR12B 2, ARS 2, CORRESP 2, EFFECT 2, SC 13D 2, SEC STAFF LETTER 2, 144/A 1, 15-12G 1, 20-F 1, 424B3 1, CERT 1, DEF 14A 1, DEFA14A 1, DRS 1, F-6 1, S-4 1, S-4/A 1, SEC STAFF ACTION 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 08:14 ET | [10-Q](/filings/0001628280-26-068013.md) | Quarterly report, period 2026-09-30 | 0001628280-26-068013 |
| 2026-10-29 | 07:00 ET | [8-K](/filings/0001193125-26-436953.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-436953 |
| 2026-10-15 | 16:17 ET | [8-K](/filings/0001104659-26-116253.md) | 5.07 Shareholder vote results | 0001104659-26-116253 |
| 2026-10-06 | 07:15 ET | [8-K](/filings/0001104659-26-113883.md) | 8.01 Other events | 0001104659-26-113883 |
| 2026-09-17 | 07:18 ET | [8-K](/filings/0001104659-26-108417.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-108417 |
| 2026-09-15 | 16:28 ET | [8-K](/filings/0001625297-26-000028.md) | 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001625297-26-000028 |
| 2026-08-13 | 17:30 ET | [SCHEDULE 13D/A](/filings/0001140361-26-032874.md) | Ownership report, active investor, amended | 0001140361-26-032874 |
| 2026-08-03 | 16:24 ET | [10-Q](/filings/0001628280-26-051895.md) | Quarterly report, period 2026-06-30 | 0001628280-26-051895 |
| 2026-08-03 | 08:32 ET | [8-K](/filings/0001193125-26-329618.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-329618 |
| 2026-08-03 | 06:50 ET | [8-K](/filings/0001193125-26-329520.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-329520 |
| 2026-08-03 | 06:40 ET | [8-K](/filings/0001193125-26-329513.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-329513 |
| 2026-05-15 | 16:01 ET | [8-K](/filings/0001625297-26-000024.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001625297-26-000024 |
| 2026-05-04 | 07:00 ET | [8-K](/filings/0001625297-26-000021.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001625297-26-000021 |
| 2026-04-30 | 16:02 ET | [10-Q](/filings/0001628280-26-028850.md) | Quarterly report, period 2026-03-31 | 0001628280-26-028850 |
| 2026-04-30 | 07:00 ET | [8-K](/filings/0001193125-26-193925.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-193925 |
| 2026-03-27 | 06:01 ET | [DEF 14A](/filings/0001104659-26-035480.md) | Proxy statement, period 2026-05-13 | 0001104659-26-035480 |
| 2026-03-17 | 16:05 ET | [8-K](/filings/0001625297-26-000015.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001625297-26-000015 |
| 2026-03-13 | 20:42 ET | [8-K](/filings/0001625297-26-000012.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001625297-26-000012 |
| 2026-03-12 | 07:01 ET | [8-K](/filings/0001625297-26-000008.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001625297-26-000008 |
| 2026-02-26 | 16:03 ET | [10-K](/filings/0001628280-26-012237.md) | Annual report, period 2025-12-31 | 0001628280-26-012237 |
| 2026-02-26 | 07:00 ET | [8-K](/filings/0001193125-26-073363.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-073363 |
| 2026-01-26 | 07:01 ET | [8-K](/filings/0001193125-26-021660.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 5.01 Change in control; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.05 Item not in the standard list; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-021660 |
| 2026-01-08 | 07:05 ET | [8-K](/filings/0001193125-26-006993.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-006993 |
| 2025-12-30 | 17:53 ET | [SCHEDULE 13D/A](/filings/0001140361-25-046912.md) | Ownership report, active investor, amended | 0001140361-25-046912 |
| 2025-12-23 | 17:49 ET | [SCHEDULE 13D/A](/filings/0001315863-25-000874.md) | Ownership report, active investor, amended | 0001315863-25-000874 |
| 2025-12-22 | 07:03 ET | [8-K](/filings/0001625297-25-000078.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001625297-25-000078 |
| 2025-12-18 | 16:04 ET | [8-K](/filings/0001625297-25-000076.md) | 5.02 Departure or appointment of officers or directors | 0001625297-25-000076 |
| 2025-12-15 | 16:04 ET | [8-K](/filings/0001625297-25-000072.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001625297-25-000072 |
| 2025-12-10 | 20:15 ET | [SCHEDULE 13D/A](/filings/0001011438-25-000594.md) | Ownership report, active investor, amended | 0001011438-25-000594 |
| 2025-11-20 | 16:07 ET | [8-K](/filings/0001625297-25-000069.md) | 1.02 Termination of a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001625297-25-000069 |
| 2025-11-14 | 09:05 ET | [8-K](/filings/0001628280-25-052210.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-25-052210 |
| 2025-11-13 | 21:15 ET | [SCHEDULE 13D/A](/filings/0001140361-25-042045.md) | Ownership report, active investor, amended | 0001140361-25-042045 |
| 2025-11-05 | 20:21 ET | [SCHEDULE 13D/A](/filings/0001011438-25-000504.md) | Ownership report, active investor, amended | 0001011438-25-000504 |
| 2025-10-30 | 16:10 ET | [8-K/A](/filings/0001625297-25-000064.md) | 2.05 Exit or disposal costs | 0001625297-25-000064 |
| 2025-10-30 | 16:09 ET | [10-Q](/filings/0001628280-25-047530.md) | Quarterly report, period 2025-09-30 | 0001628280-25-047530 |
| 2025-10-30 | 07:00 ET | [8-K](/filings/0001193125-25-257381.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-257381 |
| 2025-10-01 | 08:01 ET | [8-K](/filings/0001628280-25-043293.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-25-043293 |
| 2025-09-05 | 16:13 ET | [SCHEDULE 13D/A](/filings/0001011438-25-000461.md) | Ownership report, active investor, amended | 0001011438-25-000461 |
| 2025-08-26 | 07:45 ET | [8-K](/filings/0001625297-25-000059.md) | 2.05 Exit or disposal costs | 0001625297-25-000059 |
| 2025-08-22 | 16:58 ET | [8-K](/filings/0001625297-25-000056.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001625297-25-000056 |
| 2025-08-04 | 16:12 ET | [8-K/A](/filings/0001628280-25-037425.md) | 5.02 Departure or appointment of officers or directors | 0001628280-25-037425 |
| 2025-07-31 | 12:59 ET | [10-Q](/filings/0001625297-25-000050.md) | Quarterly report, period 2025-06-30 | 0001625297-25-000050 |
| 2025-07-31 | 07:00 ET | [8-K](/filings/0001193125-25-169947.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-169947 |
| 2025-07-29 | 15:17 ET | [SCHEDULE 13D/A](/filings/0001011438-25-000384.md) | Ownership report, active investor, amended | 0001011438-25-000384 |
| 2025-07-14 | 14:27 ET | [SCHEDULE 13D/A](/filings/0001011438-25-000346.md) | Ownership report, active investor, amended | 0001011438-25-000346 |
| 2025-06-30 | 07:03 ET | [8-K](/filings/0001625297-25-000046.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001625297-25-000046 |
| 2025-06-24 | 16:52 ET | [8-K](/filings/0001625297-25-000042.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001625297-25-000042 |
| 2025-06-18 | 15:59 ET | [SCHEDULE 13D/A](/filings/0001315863-25-000466.md) | Ownership report, active investor, amended | 0001315863-25-000466 |
| 2025-06-02 | 06:06 ET | [8-K](/filings/0001193125-25-132699.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-132699 |
| 2025-06-02 | 18:51 ET | [8-K](/filings/0001625297-25-000035.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001625297-25-000035 |

Page 1 of 9. [Older](/companies/indv/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 29, 2026, 08:21 ET. No prices; not investment advice.